Cerus Corp

Compare this stock

CERS Stock Report Card

Today's performance

42%

Performance

Score:

10/100

CERS returned -56.11% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

Score:

92/100

3 analysts offer 12-month price targets for CERS. Together, they have an average target of 0, the most optimistic target put CERS at 0 within 12-months and the most pessimistic has CERS at 0.

Sentiment

Score:

70/100

CERS had a bullish sentiment score of 69.77% across Twitter and StockTwits over the last 12 months. It had an average of 2.49 posts, 0.41 comments, and 0.90 likes per day.

Technicals

Score:

64/100

CERS receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

Score:

10/100

CERS has missed earnings 8 times in the last 20 quarters.

Profit

Score:

10/100

Out of the last 20 quarters, CERS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

Score:

41/100

CERS has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

Cerus Corp Summary

Nasdaq / CERS

Healthcare

Medical - Devices

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Power up your portfolio